Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aptose Biosciences
Special Reports
The 2025 Biotech Graveyard
Biotechs, beware: You're in for a scare.
Darren Incorvaia
Oct 31, 2025 5:00am
CEO props up Aptose's finances to keep biotech from going bust
Jun 17, 2025 10:04am
Fierce Biotech launches layoff tracker—Chutes and Ladders
Apr 8, 2022 9:30am
Aptose finally ditches APTO-253 after 3-year clinical hold
Dec 20, 2021 11:45am
After nearly 3 years, FDA lifts hold on Aptose cancer drug
Jun 29, 2018 9:05am
Aptose signs $125M-plus BET inhibitor deal with Ohm
Mar 7, 2018 9:32am
